Compare Stocks: GETY, PAX, BBOT, and BRSP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBOT BridgeBio Oncology Therapeutics	$8.09	$8.17	$7.00 ▼ $14.87	$648.09M	0.35	355,701 shs	368,245 shs
BRSP BrightSpire Capital	$5.02 +0.1%	$5.46	$4.85 ▼ $6.16	$634.50M	1.29	1.58 million shs	2.23 million shs
GETY Getty Images	$0.37 -0.3%	$0.75	$0.36 ▼ $3.21	$155.43M	2.11	4.75 million shs	2.72 million shs
PAX Patria Investments	$10.82	$11.17	$10.55 ▼ $17.80	$719.78M	0.74	954,343 shs	1.85 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBOT BridgeBio Oncology Therapeutics	0.00%	-8.28%	-0.25%	-3.58%	+808,999,900.00%
BRSP BrightSpire Capital	0.00%	-4.06%	-7.56%	-14.36%	-3.00%
GETY Getty Images	0.00%	-15.49%	-58.96%	-54.20%	-77.58%
PAX Patria Investments	0.00%	+0.19%	-2.52%	-14.74%	-18.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBOT BridgeBio Oncology Therapeutics	$8.09	$8.17	$7.00 ▼ $14.87	$648.09M	0.35	355,701 shs	368,245 shs
BRSP BrightSpire Capital	$5.02 +0.1%	$5.46	$4.85 ▼ $6.16	$634.50M	1.29	1.58 million shs	2.23 million shs
GETY Getty Images	$0.37 -0.3%	$0.75	$0.36 ▼ $3.21	$155.43M	2.11	4.75 million shs	2.72 million shs
PAX Patria Investments	$10.82	$11.17	$10.55 ▼ $17.80	$719.78M	0.74	954,343 shs	1.85 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBOT BridgeBio Oncology Therapeutics	0.00%	-8.28%	-0.25%	-3.58%	+808,999,900.00%
BRSP BrightSpire Capital	0.00%	-4.06%	-7.56%	-14.36%	-3.00%
GETY Getty Images	0.00%	-15.49%	-58.96%	-54.20%	-77.58%
PAX Patria Investments	0.00%	+0.19%	-2.52%	-14.74%	-18.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBOT BridgeBio Oncology Therapeutics	2.75	Moderate Buy	$24.80	206.55% Upside
BRSP BrightSpire Capital	2.33	Hold	$6.50	29.61% Upside
GETY Getty Images	1.80	Reduce	$3.78	919.77% Upside
PAX Patria Investments	2.33	Hold	$17.00	57.12% Upside

Current Analyst Ratings Breakdown

Latest GETY, PAX, BBOT, and BRSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	BRSP BrightSpire Capital	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $6.50
7/29/2026	BRSP BrightSpire Capital	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$6.50
7/20/2026	PAX Patria Investments	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/8/2026	BBOT BridgeBio Oncology Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight
7/8/2026	BBOT BridgeBio Oncology Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$27.00
7/6/2026	GETY Getty Images	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/22/2026	BBOT BridgeBio Oncology Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$22.00
6/18/2026	BBOT BridgeBio Oncology Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/3/2026	BRSP BrightSpire Capital	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$6.50
5/26/2026	BRSP BrightSpire Capital	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
5/18/2026	GETY Getty Images	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	$5.14 per share	N/A
BRSP BrightSpire Capital	$194.89M	3.26	$0.91 per share	5.49	$7.16 per share	0.70
GETY Getty Images	$981.29M	0.16	N/A	N/A	$1.44 per share	0.26
PAX Patria Investments	$399.23M	1.80	$3.42 per share	3.16	$9.43 per share	1.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBOT BridgeBio Oncology Therapeutics	-$134.04M	-$2.05	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BRSP BrightSpire Capital	-$31.15M	-$0.23	N/A	8.22	N/A	-20.43%	7.01%	1.80%	N/A
GETY Getty Images	-$206.12M	-$0.26	N/A	N/A	N/A	-10.94%	-17.01%	-3.70%	8/10/2026 (Estimated)
PAX Patria Investments	$73.40M	$0.44	21.64	6.81	1.28	19.91%	38.68%	15.84%	N/A

Latest GETY, PAX, BBOT, and BRSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	GETY Getty Images	$0.01	N/A	N/A	N/A	$235.23 million	N/A
7/28/2026	Q2 2026	BRSP BrightSpire Capital	$0.1488	$0.13	-$0.0188	-$0.15	$64.31 million	$48.70 million
5/12/2026	Q1 2026	BBOT BridgeBio Oncology Therapeutics	N/A	-$526.11	N/A	-$526.11	N/A	N/A
5/11/2026	Q1 2026	GETY Getty Images	$0.01	-$0.01	-$0.02	-$0.01	$238.90 million	$226.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	N/A
BRSP BrightSpire Capital	$0.64	12.76%	+16.36%	N/A	N/A
GETY Getty Images	N/A	N/A	N/A	N/A	N/A
PAX Patria Investments	$0.65	6.01%	N/A	147.73%	N/A

Latest GETY, PAX, BBOT, and BRSP Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/27/2026	PAX Patria Investments	quarterly	$0.1625	6.01%	8/10/2026	8/10/2026	9/14/2026
6/15/2026	BRSP BrightSpire Capital	quarterly	$0.16	11.73%	6/30/2026	6/30/2026	7/15/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBOT BridgeBio Oncology Therapeutics	N/A	6.16	6.16
BRSP BrightSpire Capital	2.75	0.83	0.83
GETY Getty Images	2.13	0.76	0.76
PAX Patria Investments	0.31	0.91	0.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBOT BridgeBio Oncology Therapeutics	54.89%
BRSP BrightSpire Capital	56.57%
GETY Getty Images	45.75%
PAX Patria Investments	96.27%

Insider Ownership

Company	Insider Ownership
BBOT BridgeBio Oncology Therapeutics	24.40%
BRSP BrightSpire Capital	2.81%
GETY Getty Images	12.50%
PAX Patria Investments	58.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBOT BridgeBio Oncology Therapeutics	N/A	80.11 million	60.56 million	N/A
BRSP BrightSpire Capital	50	126.52 million	122.97 million	Optionable
GETY Getty Images	1,650	418.96 million	366.59 million	Optionable
PAX Patria Investments	390	66.52 million	25.04 million	Optionable

GETY, PAX, BBOT, and BRSP Headlines

Recent News About These Companies

Patria Investments Limited: Patria Reports Second Quarter 2026 Earnings Results

August 2 at 2:00 PM | finanznachrichten.de

Patria targets $225M-$245M 2026 FRE while expecting 2026 FRE margin modestly below 58%-60%

August 1 at 12:10 PM | seekingalpha.com

Patria Investments Limited (PAX) Q2 2026 Earnings Call Transcript

August 1 at 1:00 AM | seekingalpha.com

Patria Investments (NYSE:PAX) Reaches New 12-Month Low - Should You Sell?

July 31 at 1:59 PM | marketbeat.com

Patria Investments Limited 2026 Q2 - Results - Earnings Call Presentation

July 31 at 1:32 PM | seekingalpha.com

Patria Investments (PAX) Tops Q2 Earnings and Revenue Estimates

July 31 at 8:26 AM | zacks.com

Patria Investments: Q2 Earnings Snapshot

July 31 at 7:44 AM | chron.com

Patria Reports Second Quarter 2026 Earnings Results

July 31 at 6:00 AM | globenewswire.com

Patria Announces Second Quarter 2026 Investor Call

July 29, 2026 | globenewswire.com

Patria Investments Reports Higher Q1 2026 Revenue and Expanding Balance Sheet

July 28, 2026 | tipranks.com

SEB Asset Management AB Purchases New Shares in Patria Investments Limited $PAX

July 23, 2026 | marketbeat.com

Patria Investments (NYSE:PAX) Upgraded to "Hold" at Zacks Research

July 22, 2026 | marketbeat.com

Y Intercept Hong Kong Ltd Buys New Shares in Patria Investments Limited $PAX

July 12, 2026 | marketbeat.com

Patria Investments successfully raises over USD 670m for its Secondary Opportunities Fund V

July 2, 2026 | globenewswire.com

Patria Investments Ltd. Class A

June 29, 2026 | edition.cnn.com

Patria Investments (NASDAQ:PAX) Stock, Earnings Estimates, EPS, And Revenue

June 25, 2026 | benzinga.com

Patria Investments Stock Dividends | NASDAQ:PAX | Benzinga

June 24, 2026 | benzinga.com

Senior Managing Partner & Chairman of Patria Investments Picks Up 24% More Stock

June 7, 2026 | finance.yahoo.com

Olimpio Matarazzo Neto Buys 50,000 Shares of Patria Investments (NYSE:PAX) Stock

June 6, 2026 | insidertrades.com

Insider Buying: Patria Investments (NYSE:PAX) Director Acquires 15,000 Shares of Stock

June 4, 2026 | insidertrades.com

Olimpio Matarazzo Neto Purchases 15,000 Shares of Patria Investments (NYSE:PAX) Stock

June 2, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GETY, PAX, BBOT, and BRSP Company Descriptions

BridgeBio Oncology Therapeutics NASDAQ:BBOT

$8.09 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$8.30 +0.21 (+2.53%)

As of 07/31/2026 07:34 PM Eastern

We are a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value. Our sponsor is an affiliate of Cormorant, a leading life sciences focused investment firm with over $2 billion in assets under management as of December 31, 2022. Our Chairperson and Chief Executive Officer, Bihua Chen, founded Cormorant and is the managing member of Cormorant. Since its inception in 2013, Cormorant has focused on the healthcare industry and invests, throughout their growth cycle, in companies that discover and develop therapeutic drugs or medical technology. Cormorant is an active life-science investor with investments in over 100 privately held, life science-focused companies over this period. Of these investments, over 50 have completed initial public offerings. Notable successes include Prometheus Biosciences, Inc., Turning Point Therapeutics, Inc., and MyoKardia, Inc., each of which has been acquired for more than $4 billion. Other notable successes include BridgeBio Pharma Inc. and Apellis Pharmaceuticals Inc., each of which is a public company with a market capitalization greater than $1 billion. Our executive offices are located at 200 Clarendon Street, 52nd Floor, Boston, MA.

BrightSpire Capital NYSE:BRSP

$5.01 +0.01 (+0.10%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$5.01 0.00 (0.00%)

As of 07/31/2026 07:34 PM Eastern

BrightSpire Capital, Inc. operates as a commercial real estate (CRE) credit real estate investment trust in the United States and Europe. The company operates through Senior and Mezzanine Loans and Preferred Equity; Net Leased and Other Real Estate; and Corporate and Other segments. It focuses on originating, acquiring, financing, and managing a diversified portfolio of CRE debt investments consisting of first mortgage loans, senior loans, debt securities, mezzanine loans, and preferred equity investments, as well as net leased properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was formerly known as Colony Credit Real Estate, Inc. and changed its name to BrightSpire Capital, Inc. in June 2021. BrightSpire Capital, Inc. was incorporated in 2017 and is headquartered in New York, New York.

Getty Images NYSE:GETY

$0.37 0.00 (-0.27%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$0.37 0.00 (-0.81%)

As of 07/31/2026 07:56 PM Eastern

Getty Images Holdings, Inc. offers creative and editorial visual content solutions in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Its products include Getty Images that offers creative and editorial content including stills, music and video which focuses on corporate, agency, and media customers; iStock.com, an e-commerce offering where customers have access to creative stills and video; Unsplash.com, a platform offering free stock photo downloads and paid subscriptions targeted to the high-growth prosumer and semi-professional creator segments; and Unsplash+ that provides access to unique model released content with expanded legal protections. In addition, it maintains privately-owned photographic archives covering news, sport, and entertainment, as well as variety of subjects, including lifestyle, business, science, health, wellness, beauty, sports, transportation, and travel. Further, the company provides music licensing, and digital asset management and distribution services. It serves media outlets, advertising agencies and corporations, individual creators, and prosumers. The company was formerly known as Getty Images, Inc. Getty Images Holdings, Inc. was founded in 1995 and is headquartered in Seattle, Washington.

Patria Investments NYSE:PAX

$10.82 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$10.81 -0.01 (-0.09%)

As of 07/31/2026 07:34 PM Eastern

Patria Investments Limited operates as a private market investment firm focused on investing in Latin America. The company offers asset management services to investors focusing on private equity funds, infrastructure development funds, co-investments funds, constructivist equity funds, and real estate and credit funds. Patria Investments Limited was founded in 1994 and is headquartered in Grand Cayman, the Cayman Islands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GETY, PAX, BBOT, and BRSP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GETY, PAX, BBOT, and BRSP Earnings

Compare Dividends

Latest GETY, PAX, BBOT, and BRSP Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GETY, PAX, BBOT, and BRSP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GETY, PAX, BBOT, and BRSP Company Descriptions

BridgeBio Oncology Therapeutics NASDAQ:BBOT

BrightSpire Capital NYSE:BRSP

Getty Images NYSE:GETY

Patria Investments NYSE:PAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools